Gettinger S, et al. - Nivolumab, a programmed death-1 (PD-1) inhibitor antibody, was shown to improve overall survival (OS) vs docetaxel in pretreated advanced non–small-cell lung cancer (NSCLC) in two phase III studies. In this current study, five-year follow-up results from an early phase I study of nivolumab in this patient population were reported and features of 5-year survivors were mentioned. In a proportion of patients with pretreated advanced NSCLC, administration of nivolumab 1, 3, or 10 mg/kg every 2 weeks in 8-week cycles for up to 96 weeks provided long-term OS and durable responses. In addition, baseline and on-treatment features were noted to show diversity among long-term survivors.